Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 17CNS 3Lymphoid 2Plasma cell 1Other solid neoplasm 1Genitourinary 1Endocrine 1

Conditions

Lymphoma 2982Precursor Cell Lymphoblastic Leukemia-Lymphoma 2499Lymphoma, Non-Hodgkin 2268Leukemia, Lymphocytic, Chronic, B-Cell 1992Lymphoma, Follicular 1847Lymphoma, Large B-Cell, Diffuse 1785Leukemia 1341Hodgkin Disease 1293Lymphoma, Mantle-Cell 1193Leukemia, Myeloid, Acute 979Burkitt Lymphoma 956Multiple Myeloma 866Lymphoma, B-Cell, Marginal Zone 853Recurrence 841Lymphoma, B-Cell 756Myelodysplastic Syndromes 683Neoplasms 595Lymphoma, T-Cell, Cutaneous 543Waldenstrom Macroglobulinemia 514Lymphoma, Large-Cell, Immunoblastic 490Mycosis Fungoides 438Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 414Lymphoma, Large-Cell, Anaplastic 390Sezary Syndrome 364Lymphoma, T-Cell, Peripheral 352Hematologic Neoplasms 351Leukemia, Myelogenous, Chronic, BCR-ABL Positive 334Myeloproliferative Disorders 328Neoplasms, Plasma Cell 309Blast Crisis 284

Interventions

Crizotinib 1BAY 1895344 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Rhabdomyosarcoma, Alveolar × Lymphoid × Clear all
NCT05071209 2026-01-23

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
31 enrolled 14 charts
LymphoidSarcoma

Lymphoma, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar

NCT01524926 2023-12-11

CREATE

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
582 enrolled
LymphoidPlasma cellSarcoma

Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Sarcoma, Clear Cell, Rhabdomyosarcoma, Alveolar, Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡